6C1 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - CytomX Therapeutics Inc

Watchlist Manager

Watchlist

Price: 2.998 EUR -0.93% Market Closed

Market Cap: €233.6m

C	CytomX Therapeutics Inc F:6C1	US
G	GH Research PLC F:1KA	IE
	Mammoth Energy Services Inc F:5M8	US
	Avant Brands Inc F:1BU	CA
B	Business Engineering Corp XMUN:TBY	JP
I	Intrepid Potash Inc F:58I1	US
E	Enzo Biochem Inc F:EZB	US

Profitability Summary

CytomX Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Low 3Y Average Gross Margin

Negative Operating Margin

-476%

Negative 3Y Average Operating Margin

-52%

Declining Operating Margin

-112% > -476%

Negative Net Margin

-452%

Negative 3Y Average Net Margin

-46%

Declining Net Margin

-102% > -452%

Negative Free Cash Flow Margin

-451%

Negative 3Y Average Free Cash Flow Margin

-111%

Declining Free Cash Flow Margin

-87% > -451%

Negative ROE

-39%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-24%

Declining ROIC

-235% > -266%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.